Investegate announcements from Novo Nordisk A/S, Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001 – a cell therapy designed to restore heart function in people with advanced heart failure
Heartseed Inc. (Heartseed) and Novo Nordisk A/S today announced that Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated 4-week data on the patient .
While historically lacking in foreign investments, Japan’s biotech scene is now thriving with global investors showing increasing interest. Here are five of the hottest Japanese private companies innovating in the healthcare space.